Zoetis Stock Falls After $160 Million Acquisition Announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2024
0mins
Should l Buy ZTS?
Source: barron's
Zoetis Inc shares have decreased by 3.00% as the stock hits a 20-day low amid broader market declines.
The decline follows the announcement of Zoetis's acquisition of Neogen's animal genomics division for $160 million, which has raised concerns among investors about the financial implications of the deal. This acquisition is part of Zoetis's strategy to enhance its portfolio in animal health, but the immediate market reaction has been negative, reflecting investor caution in a volatile market environment.
As Zoetis continues to expand its capabilities in animal health, the market will be closely watching how this acquisition impacts its financial performance and strategic direction in the coming quarters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 120.490
Low
130.00
Averages
154.20
High
200.00
Current: 120.490
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Strong Dividends and Innovation Drive Healthcare Stocks
- Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
- Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
- Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
- Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.
See More
Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis
- Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
- Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
- Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
- Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.
See More
Zoetis CFO to Participate in Investor Conferences
- Investor Conference Schedule: Zoetis CFO Wetteny Joseph will participate in the Leerink Global Healthcare Conference on March 9, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, showcasing the company's leadership in animal health.
- Live Webcast Access: Interested investors can access live audio webcasts of the presentations via the Zoetis investor website, ensuring transparency and enhancing engagement with stakeholders.
- Company Background: With nearly 75 years of history, Zoetis is dedicated to advancing animal health, supporting veterinarians, livestock producers, and pet owners in over 100 countries, demonstrating its significant industry impact.
- Future Development Vision: Zoetis aims to set new standards for animal care through scientific R&D, advanced manufacturing, and commercial excellence, reflecting its customer obsession and purpose-driven corporate culture.
See More
Zoetis Stock Falls 1.4% Following $160 Million Acquisition of Neogen's Animal Genomics Division
- Stock Performance: ZOETIS shares have decreased by 1.4% following a recent deal announcement.
- Acquisition Details: The company is set to acquire Neogen's animal genomics unit for a total of $160 million.
See More
High ROE Stocks Recommended Amid Market Volatility
- Market Volatility Context: This week, the markets experienced significant fluctuations due to rising tensions between the U.S. and Iran and concerns about AI's impact, with GDP growth at only 1.4%, well below the expected 2.5%, leading to investor anxiety.
- Tariff Cancellation Impact: The U.S. Supreme Court's annulment of Trump's tariffs sparked a market rebound; however, concerns over NVIDIA's deal with OpenAI dampened the momentum, reflecting ongoing uncertainty in the market outlook.
- High ROE Stock Picks: Stocks such as Ross Stores, Globe Life, Banco Bilbao, Zoetis, and TE Connectivity are highlighted for their high ROE, with long-term earnings growth expectations of 8.1%, 17.1%, 9.3%, and 12%, indicating strong profitability and financial health in their respective sectors.
- Importance of ROE: ROE serves as a critical metric for assessing a company's profitability, enabling investors to identify firms that effectively deploy capital to generate returns for shareholders, which is particularly vital in the current market climate.
See More
Zacks Research Daily: Tech Stock Updates
- NVIDIA Strong Performance: NVIDIA's stock has risen 44.2% over the past year, slightly trailing the semiconductor industry's 45.1% growth, benefiting from robust demand for AI and high-performance computing, particularly with GPUs based on its Hopper and Blackwell architectures driving data center revenue growth.
- Microsoft AI Business Growth: Microsoft shares have dipped 0.2%, yet its AI business momentum and Copilot adoption are propelling Azure cloud infrastructure expansion, with strong Office 365 commercial demand, although Azure growth guidance has slowed to 37-38%, indicating potential demand saturation risks.
- JPMorgan Sustained Growth: JPMorgan's stock has increased by 14.5%, outperforming the investment banking industry's 24.9% growth, with expectations for nearly a 9% rise in net interest income for 2026, despite concerns over weak asset quality and market volatility potentially impacting non-interest income.
- Star Group Acquisition-Driven Growth: Star Group's shares have gained 6.9%, operating in a fragmented heating fuel market in the Northeast and Mid-Atlantic, leveraging acquisitions to enhance operational leverage, although facing risks from weather volatility and regulatory pressures.
See More
Strong Dividends and Innovation Drive Healthcare Stocks
- Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
- Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
- Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
- Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.
See More
Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis
- Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
- Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
- Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
- Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.
See More
Zoetis CFO to Participate in Investor Conferences
- Investor Conference Schedule: Zoetis CFO Wetteny Joseph will participate in the Leerink Global Healthcare Conference on March 9, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, showcasing the company's leadership in animal health.
- Live Webcast Access: Interested investors can access live audio webcasts of the presentations via the Zoetis investor website, ensuring transparency and enhancing engagement with stakeholders.
- Company Background: With nearly 75 years of history, Zoetis is dedicated to advancing animal health, supporting veterinarians, livestock producers, and pet owners in over 100 countries, demonstrating its significant industry impact.
- Future Development Vision: Zoetis aims to set new standards for animal care through scientific R&D, advanced manufacturing, and commercial excellence, reflecting its customer obsession and purpose-driven corporate culture.
See More
Zoetis Stock Falls 1.4% Following $160 Million Acquisition of Neogen's Animal Genomics Division
- Stock Performance: ZOETIS shares have decreased by 1.4% following a recent deal announcement.
- Acquisition Details: The company is set to acquire Neogen's animal genomics unit for a total of $160 million.
See More
High ROE Stocks Recommended Amid Market Volatility
- Market Volatility Context: This week, the markets experienced significant fluctuations due to rising tensions between the U.S. and Iran and concerns about AI's impact, with GDP growth at only 1.4%, well below the expected 2.5%, leading to investor anxiety.
- Tariff Cancellation Impact: The U.S. Supreme Court's annulment of Trump's tariffs sparked a market rebound; however, concerns over NVIDIA's deal with OpenAI dampened the momentum, reflecting ongoing uncertainty in the market outlook.
- High ROE Stock Picks: Stocks such as Ross Stores, Globe Life, Banco Bilbao, Zoetis, and TE Connectivity are highlighted for their high ROE, with long-term earnings growth expectations of 8.1%, 17.1%, 9.3%, and 12%, indicating strong profitability and financial health in their respective sectors.
- Importance of ROE: ROE serves as a critical metric for assessing a company's profitability, enabling investors to identify firms that effectively deploy capital to generate returns for shareholders, which is particularly vital in the current market climate.
See More
Zacks Research Daily: Tech Stock Updates
- NVIDIA Strong Performance: NVIDIA's stock has risen 44.2% over the past year, slightly trailing the semiconductor industry's 45.1% growth, benefiting from robust demand for AI and high-performance computing, particularly with GPUs based on its Hopper and Blackwell architectures driving data center revenue growth.
- Microsoft AI Business Growth: Microsoft shares have dipped 0.2%, yet its AI business momentum and Copilot adoption are propelling Azure cloud infrastructure expansion, with strong Office 365 commercial demand, although Azure growth guidance has slowed to 37-38%, indicating potential demand saturation risks.
- JPMorgan Sustained Growth: JPMorgan's stock has increased by 14.5%, outperforming the investment banking industry's 24.9% growth, with expectations for nearly a 9% rise in net interest income for 2026, despite concerns over weak asset quality and market volatility potentially impacting non-interest income.
- Star Group Acquisition-Driven Growth: Star Group's shares have gained 6.9%, operating in a fragmented heating fuel market in the Northeast and Mid-Atlantic, leveraging acquisitions to enhance operational leverage, although facing risks from weather volatility and regulatory pressures.
See More
